Business
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT-2 enrollment completion expected in H2 2026; topline data expected in H2 2027 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2 2026$458 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSW
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"image","alt":"4D Molecular Therapeutics, Inc.","displaySize":"","headline":null,"caption":"4D Molecular Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/77c43650e1f3f7dcc5fea422c8ad89a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m_yDp5ylEZcXMIbdgu5apQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/77c43650e1f3f7dcc5fea422c8ad89a8","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":96,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"4FRONT-2 enrollment completion expected in H2 2026; topline data expected in H2 2027 ","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2 2026","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"$458 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":391,"olType":false},{"type":"text","content":"EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2026 financial results, provided operational highlights and outlined expected upcoming milestones. ","length":424,"tagName":"p"},{"type":"text","content":"“We started 2026 with strong execution, completing enrollment in 4FRONT-1 ahead of schedule reflecting strong investigator and patient enthusiasm for 4D-150,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. “For the remainder of the year, we look forward to completing 4FRONT-2 enrollment, initiating our global Phase 3 ...